Literature DB >> 31762516

Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis.

Wenli Feng1, Jing Yang1, Zhiqin Xi1, Ying Ji1, Xin Zhu1, Lu Yang1, Yan Ma1.   

Abstract

Vulvovaginal candidiasis (VVC), caused by Candida albicans, affects women's health and life. We aimed to explore the correlation between ERG3 as well as Efg1 mutation/overexpression and azoles-resistance, and the correlation between ERG3 and Efg1 mRNA expression in C. albicans. First, C. albicans was isolated from clinical VVC patients. ERG3 and Efg1 mutations were detected by polymerase chain reaction (PCR) and sequencing, and the expression levels of these two genes were also identified by qRT-PCR. Correlations between mutation/overexpression of ERG3/Efg1 and azoles-resistance as well as ERG3 and Efg1 mRNA expression were analyzed. Based on the ERG3 sequencing, the results showed that there were 2 missense mutation sites, 1 nonsense mutation site, and 4 silent mutation sites, while 1 missense mutation sites, 1 nonsense mutation site, and 12 silent mutation sites were found in Efg1. Furthermore, the mRNA levels of ERG3 gene in the strains sensitive to FCA, ITR or VRC were higher than those in the strains resistant to FCA, ITR, VRC (P < 0.05). While for the mRNA levels of Efg1, susceptible strains were lower than resistant strains. Besides, there was a significant linear negative correlation between ERG3 and Efg1 mRNA expression (r = - 0.614, P < 0.001). © Association of Microbiologists of India 2019.

Entities:  

Keywords:  Azoles; Candida albicans; Drug resistance; ERG3; Efg1

Year:  2019        PMID: 31762516      PMCID: PMC6842391          DOI: 10.1007/s12088-019-00833-x

Source DB:  PubMed          Journal:  Indian J Microbiol        ISSN: 0046-8991            Impact factor:   2.461


  22 in total

Review 1.  An update on antifungal targets and mechanisms of resistance in Candida albicans.

Authors:  Robert A Akins
Journal:  Med Mycol       Date:  2005-06       Impact factor: 4.076

2.  Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans.

Authors:  Hsiu-Jung Lo; Jang-Shiun Wang; Chih-Yang Lin; Chia-Geun Chen; Ting-Yin Hsiao; Chia-Tung Hsu; Chia-Li Su; Ming-Ji Fann; Yu-Tai Ching; Yun-Liang Yang
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 3.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

4.  Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans.

Authors:  Wenli Feng; Jing Yang; Zhiqin Xi; Zusha Qiao; Yaping Lv; Yiru Wang; Yan Ma; Yanqing Wang; Wen Cen
Journal:  Microb Drug Resist       Date:  2016-12-15       Impact factor: 3.431

Review 5.  Recurrent vulvovaginal candidiasis: A review of guideline recommendations.

Authors:  Alexia Matheson; Danielle Mazza
Journal:  Aust N Z J Obstet Gynaecol       Date:  2017-03-15       Impact factor: 2.100

6.  Resistance mechanisms in clinical isolates of Candida albicans.

Authors:  Theodore C White; Scott Holleman; Francis Dy; Laurence F Mirels; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Morphogenic regulator EFG1 affects the drug susceptibilities of pathogenic Candida albicans.

Authors:  Tulika Prasad; Saif Hameed; Raman Manoharlal; Sudipta Biswas; Chinmay K Mukhopadhyay; Shyamal K Goswami; Rajendra Prasad
Journal:  FEMS Yeast Res       Date:  2010-05-29       Impact factor: 2.796

8.  ERG11 mutations and upregulation in clinical itraconazole-resistant isolates of Candida krusei.

Authors:  Wenli Feng; Jing Yang; Yiru Wang; Jinyu Chen; Zhiqin Xi; Zusha Qiao
Journal:  Can J Microbiol       Date:  2016-07-14       Impact factor: 2.419

9.  Nucleotide substitutions in the Candida albicans ERG11 gene of azole-susceptible and azole-resistant clinical isolates.

Authors:  Joanna Katarzyna Strzelczyk; Anna Slemp-Migiel; Magdalena Rother; Karolina Gołąbek; Andrzej Wiczkowski
Journal:  Acta Biochim Pol       Date:  2013-12-16       Impact factor: 2.149

Review 10.  Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Authors:  Sarah G Whaley; Elizabeth L Berkow; Jeffrey M Rybak; Andrew T Nishimoto; Katherine S Barker; P David Rogers
Journal:  Front Microbiol       Date:  2017-01-12       Impact factor: 5.640

View more
  4 in total

1.  Combination Effect of Novel Bimetallic Ag-Ni Nanoparticles with Fluconazole against Candida albicans.

Authors:  Majid Rasool Kamli; Elham A Alzahrani; Soha M Albukhari; Aijaz Ahmad; Jamal S M Sabir; Maqsood Ahmad Malik
Journal:  J Fungi (Basel)       Date:  2022-07-14

Review 2.  Distribution and antifungal susceptibility pattern of Candida species from mainland China: A systematic analysis.

Authors:  Hazrat Bilal; Muhammad Shafiq; Bing Hou; Rehmat Islam; Muhammad Nadeem Khan; Rahat Ullah Khan; Yuebin Zeng
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

3.  Identification and functional characterization of ORF19.5274, a novel gene involved in both azoles susceptibility and hypha development in Candida albicans.

Authors:  Mingjiao Huang; Longbing Yang; Luoxiong Zhou; Chaoqin Sun; Wenjing Zhao; Jian Peng; Zhenlong Jiao; Chunren Tian; Guo Guo
Journal:  Front Microbiol       Date:  2022-10-03       Impact factor: 6.064

4.  The effects of secreted aspartyl proteinase inhibitor ritonavir on azoles-resistant strains of Candida albicans as well as regulatory role of SAP2 and ERG11.

Authors:  Wenli Feng; Jing Yang; Yan Ma; Zhiqin Xi; Xiaoqin Zhao; Xiaoxia Zhao; Min Zhao
Journal:  Immun Inflamm Dis       Date:  2021-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.